SPI1 + CD68 + macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Guofei Deng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Center, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Biomarkers, Tumor, Immunotherapy, Antigens, Differentiation, Myelomonocytic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shenzhen, Sanming Project of Medicine in Shenzhen.
Abstract (Originalsprache)
Background
Tumor-associated macrophages (TAMs) have been demonstrated to be associated with tumor progression. However, the different subpopulations of TAMs and their roles in gastric cancer (GC) remain poorly understood. This study aims to assess the effects of Spi-1 proto-oncogene (SPI1) + CD68 + TAMs in GC.
Methods
The distribution of SPI1 + CD68 + TAMs in GC tissue was estimated by immunohistochemistry, immunofluorescence, and flow cytometry. Single-cell transcriptome analysis and multiplex fluorescence immunohistochemistry were applied to explore the role of SPI1 + CD68 + TAMs in an immune contexture. SPI1 overexpression or knockdown cells were constructed to evaluate its role in macrophage polarization and angiogenesis in vitro and in vivo. Chromatin immunoprecipitation was used to verify the mechanism of SPI1 transcriptional function. The effect of combined antiangiogenic and immunotherapy was further validated using mouse peritoneal metastasis models.
Results
Single-cell transcriptome analysis and immunohistochemistry demonstrated that SPI1 was expressed in macrophages, with a higher enrichment in metastatic lesions than in primary tumors. Higher SPI1 + CD68 + TAMs infiltration was associated with poor overall survival. Mechanically, SPI1 promoted the M2-type macrophage polarization. SPI1 could bind to the promoter of vascular endothelial growth factor A and facilitate angiogenesis. Moreover, the level of SPI1 + CD68 + TAMs infiltration was closely related to the efficacy of immunotherapy, especially when combined with antiangiogenic therapy.
Conclusions
The present study showed that SPI1 + CD68 + TAMs are a promising biomarker for predicting prognosis, antiangiogenic drug sensitivity, and combination target of immunotherapy in patients with GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Diseases Center, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, Guangdong, China.
- Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.
- Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China.
- Digestive Diseases Center, The Seventh Affiliated Hospital Sun Yat-sen University, Shenzhen, Guangdong, China ysc19911991@163.com zhchangh@mail.sysu.edu.cn mingyu9318@163.com heyulong@mail.sysu.edu.cn.
- Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
ORCID-Profile: Songcheng Yin
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shenzhen
- Sanming Project of Medicine in Shenzhen
- Guangdong Provincial Key Laboratory of Digestive Cancer Research
- Shenzhen Sustainable Project
- Shenzhen Key Medical Discipline Construction Fund
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen excellent Science and Technology Innovation Talent training Project
Zitieren
APA
Deng, G., Wang, P., Su, R., Sun, X., Wu, Z., Huang, Z., Gu, L., Yu, H., Zhao, Z., He, Y., Huo, M., Zhang, C., & Yin, S. (2024). SPI1 + CD68 + macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009983
Vancouver
Deng G, Wang P, Su R, Sun X, Wu Z, Huang Z, et al. SPI1 + CD68 + macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009983
BibTeX
@article{Deng2024,
author = {Deng, Guofei and Wang, Pengliang and Su, Rishun and Sun, Xuezeng and Wu, Zizhen and Huang, Zhangsen and Gu, Liang and Yu, Hong and Zhao, Zhenzhen and He, Yulong and Huo, Mingyu and Zhang, Changhua and Yin, Songcheng},
title = {SPI1 + CD68 + macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009983}
}
EUVIMED